ALK and non-small cell lung carcinoma: Targeted therapies against specific molecular mutations, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and other driver genes, have rapidly advanced, improving the prognosis and quality of life of NSCLC patients (2).